Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04013932
Other study ID # Pro00094163
Secondary ID 5R34MH106663
Status Completed
Phase N/A
First received
Last updated
Start date August 6, 2019
Est. completion date October 27, 2020

Study information

Verified date January 2022
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to pilot test a culturally tailored Family Psychoeducation model (KUPAA) for adults with psychotic disorders and their relatives that is appropriate for cultural settings inclusive of both traditional and biomedical ideas about mental illness and that incorporates relatives as co-facilitators of the intervention.


Description:

Family psychoeducation (FPE) is an evidence-based practice used in high-income countries to help individuals with psychotic disorders and their relatives to cope more effectively with the illness. FPE has never been tested in a low-resource country nor have the mechanisms of action for this psychosocial intervention been fully identified in any context. The goal of this study is to pilot test a culturally tailored Family Psychoeducation model (called KUPAA) for adults with psychotic disorders and their relatives that is appropriate for cultural settings inclusive of both traditional and biomedical ideas about mental illness and that incorporates relatives as co-facilitators of the intervention. Formative research has already been conducted to culturally tailor the model for the Tanzanian context. This pilot study is a small randomized controlled trial (RCT) with 72 patient/relative dyads that will test the KUPAA intervention to a) assess the feasibility and acceptability of the adapted family psychoeducation intervention for 12 weeks, and b) explore its impact on patient relapse, quality of life and disability. Primary study objectives 1. To pilot test the KUPAA intervention to explore its impact on patient relapse, quality of life and disability Secondary study objectives 2. To elucidate the mechanisms of action for KUPAA (e.g. hopefulness, self-efficacy) and refine the mediation and study outcome measures for a future R01/fully powered clinical trial


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date October 27, 2020
Est. primary completion date October 27, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Patient Inclusion Criteria: - Attending outpatient psychiatric services at Muhimbili National Hospital (MNH) or Mbeya Zonal Referral Hospital (MZRH). - ICD-10 Diagnosis of a non-organic psychotic disorder: - F20 Schizophrenia - F21 Schizotypal disorder - F22 Delusional disorders - F25 Schizoaffective disorders - Age 18-50 at the time of informed consent - Hospitalization or relapse (confirmed by attending psychiatrist or medical officer) within the past 12 months. Patient Exclusion Criteria: - F23 Brief psychotic disorder - F28 Other psychotic disorder not due to a substance or known physiological condition - F29 Unspecified psychosis not due to a substance or known physiological condition - Epileptic psychoses - Bipolar disorder and mania - Co-morbid developmental disorder, dementia, or other severe cognitive deficit that renders the individual unable to provided informed consent. Caregiver Inclusion Criteria: - Age 18 or older at time of consenting process - Patient agrees that this person can be their paired partner for KUPAA if the pair is randomized to the intervention group

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
KUPAA Intervention Group (Culturally Tailored Family Psychoeducation)
KUPAA is composed of 3 key components: 1-2 Joining sessions [~30 to 45 minutes each] give the facilitator and participants a chance to get to know each other before KUPAA groups begin and allows time for questions. Educational Workshop is an interactive, one day workshop offering information about biological, psychological and social aspects of mental illness; the nature, effects and side effects of psychiatric treatments; what families can do to help recovery and prevent relapse; and guidelines for managing mental illnesses. 12 Family psychoeducation group sessions [~1.5 hours each session] occur weekly in multi-family groups. These sessions follow an empirically tested format and focus on solving problems that interfere with treatment, illness, and symptoms management and that support coping skills and personal care. Case management may also be provided.

Locations

Country Name City State
Tanzania Muhimbili University of Health and Allied Sciences (MUHAS) Dar Es Salaam
Tanzania Mbeya Zonal Referral Hospital Mbeya

Sponsors (2)

Lead Sponsor Collaborator
Duke University National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

Tanzania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Patient Participants Who Experience Illness Relapse Patient relapse measured by hospitalization or non-hospitalized relapse, defined as a new illness episode with recurrence of symptoms after one month of controlled symptoms. Relapse is measured from immediate post-intervention to endline (~6-7 months post-intervention)
Primary Change From Baseline to Endline in Disability, as Measured by the World Health Organization Disability Assessment Schedule Version 2.0 (WHODAS 2.0) Scores are measured from the 36-item WHODAS 2.0, the World Health Organization Disability Assessment Schedule, which measures health and disability. WHODAS 2.0 This self-report assessment measures difficulties performing daily activities over the past 30 days. It consists of 36 Likert-formatted questions across six domains: understanding and communicating, getting around, self-care, getting along with others, life activities, and participation in society. WHO's guidelines for the complex scoring method were used to create the total score, ranging from 0 (no disability) to 100 (full disability). Higher scores indicate worse outcomes. Baseline (pre-intervention) and Endline (~6-7 months post-intervention)
Primary Change From Baseline to Endline in Quality of Life, as Measured by the World Health Organization Quality of Life- Abbreviated Version (WHOQOL-BREF) Raw total scores are measured from the 26-item WHOQOL-BREF (the abbreviated version of the World Health Organization Quality of Life 100 scale). This self-report assessment has 26 questions across four domains; physical health, psychological, social relationships, and environment. Each item is rated on a five-point Likert scale (1-5) ranging from 1 (not at all, very dissatisfied, very poor) to 5 (an extreme amount, very satisfied, very good); three items needed reverse scoring. The range is 26 (min) to 130 (max) for the total raw score. Higher scores indicate a better outcome. Baseline (pre-intervention) and Endline (~6-7 months post-intervention)
See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Enrolling by invitation NCT03090490 - 10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals N/A
Completed NCT03323437 - Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia Phase 4
Completed NCT06040944 - Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
Recruiting NCT04452175 - Cigarette Consumption After switchinG to High or Low Nicotine strENght E-cigaretteS In Smokers With Schizophrenia N/A
Completed NCT03501888 - Cognitive Behavior Therapy for Patients With Psychoses. N/A
Completed NCT05601063 - Ascertaining Diagnosis Classification With Elicited Speech
Recruiting NCT05877716 - EPI-MINN: Targeting Cognition and Motivation - National N/A
Completed NCT03955549 - Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial Phase 3
Completed NCT03235908 - Copeptin in Outcome Prediction of an Acute Psychotic Episode
Recruiting NCT05622201 - A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults Phase 2
Recruiting NCT05491486 - Mindfulness, Empathy and the Oxytocinergic System in Persons With Schizophrenia N/A
Recruiting NCT04916496 - Acceptance and Commitment Therapy-based Lifestyle Counselling Programme for Early Psychosis on Physical Activity N/A
Recruiting NCT04104347 - Metacognitive Training and Insight in Schizophrenia N/A
Recruiting NCT05664594 - State Representation in Early Psychosis - Project 4 N/A
Recruiting NCT05538832 - Remote State Representation in Early Psychosis Early Phase 1
Completed NCT02220504 - 3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals N/A
Completed NCT04665401 - Personalizing Interventions Using Real-World Interactions N/A
Recruiting NCT03919760 - Early Psychosis Intervention - Spreading Evidence-based Treatment